SITE002-0025

SITE002 (USA) › SITE002-0025

SITE002-0025

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2025-09-22

enrolled

AEs

8

Serious

1

Dropout signal

–

Adverse events

8

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-10 (study day 345); relationship: RELATED

moderate assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-17 (study day 324); relationship: NOT RELATED

mild assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-21 (study day 266); relationship: RELATED

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-08-15 (study day 138); relationship: not assessed

moderate assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-10 (study day 133); relationship: not assessed

mild assessed

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-07-27 (study day 119); relationship: NOT RELATED; serious criteria: hospitalization

severe serious assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-05-26 (study day 57); relationship: NOT RELATED

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-04-07 (study day 8); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.